Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Pharmacogenomics: The End of Trial-and-Error Medicine?

Author(s):  Vail Jane

Issue:  Jan/Feb 2007 - Pediatric Patients
View All Articles in Issue

Page(s):  59-65

Pharmacogenomics: The End of Trial-and-Error Medicine? Page 1
Pharmacogenomics: The End of Trial-and-Error Medicine? Page 2
Pharmacogenomics: The End of Trial-and-Error Medicine? Page 3
Pharmacogenomics: The End of Trial-and-Error Medicine? Page 4
Pharmacogenomics: The End of Trial-and-Error Medicine? Page 5
Pharmacogenomics: The End of Trial-and-Error Medicine? Page 6
Pharmacogenomics: The End of Trial-and-Error Medicine? Page 7

Download in electronic PDF format for $75

Abstract:  “The right dose of the right drug for the right indication for the right patient at the right time.” In those words, Dr. Felix Frueh captured the essence of pharmacogenomics and the goal of all compounding pharmacists. Pharmacogenomics provides the tools for prescribing personalized drug therapy that will improve treatment outcomes, decrease the incidence of drug-related adverse effects, and ultimately reduce the cost of medical care. The use of pharmacogenomics in clinical practice is changing as new discoveries make it possible and cost-effective to identify a patient’s unique genetic makeup and apply this information to treating medical ailments. With a prescription and the patient’s pharmacogenomic profile in mind, a compounding pharmacist can prepare a customized medication that delivers that patient’s unique best dosage in the optimal dosage form.

Related Keywords: PERSONALIZED MEDICINE, INDIVIDUALIZED MEDICINE, PHARMACOGENOMICS, GENOMICS, GENOME, GENETIC TESTING, RESEARCH, FDA, US FOOD AND DRUG ADMINISTRATION, TRIAL, CUSTOMIZED, JANET WOODCOCK

Related Categories: LEGAL, TECHNOLOGY, PROFESSIONAL ISSUES, PREVENTIVE MEDICINE/WELLNESS

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Pharmacogenomics: The End of Trial-and-Error Medicine?
Vail Jane
Jan/Feb 2007
Pg. 59-65

Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management
Soni Abhishek
, Gowthamarajan Kuppusamy, Radhakrishnan Arun
Mar/Apr 2018
Pg. 108-121

Pharmacogenomics as a Competitive Strategy for Compounding Pharmacies
Maham Nicole Y
Nov/Dec 2022
Pg. 474-479

Biotechnology, Nanotechnology, and Pharmacogenomics and Pharmaceutical Compounding, Part 2
Allen Loyd V
Jul/Aug 2015
Pg. 280-287

Pharmacogenomics: Precision Pharmacy in 503A Compounding
Drummond Joseph
, Bennet Daron, Allen Loyd V Jr
Mar/Apr 2018
Pg. 95-107

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

Single-Patient Trials, Extemporaneously Compounded Products and Pharmaceutical Care
Fassett William E
Nov/Dec 2003
Pg. 441-447

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Quality Control Analytical Methods: End-preparation Assessments and Tests for Compounded Sterile Preparations
McElhiney Linda F
Jul/Aug 2013
Pg. 307-311

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

Basics: A Review: In Situ Gel Dosage Forms for Herbal Medicine Delivery
Rachmawati Putriana
Jan/Feb 2023
Pg. 24-29

The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

Utilization of Compounded Medications in an Oral Medicine Practice
Stock Shannon
, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
Mar/Apr 2016
Pg. 155-158

Basics of Pharmacogenomics for the Compounding Pharmacist
Kupiec Thomas C
, Raj Vishnu
Jul/Aug 2005
Pg. 303-306

Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration
Kupiec Tom
, Kemp Jesse
Jul/Aug 2007
Pg. 326-327

Return to Top